鑱蜂綅鎻忚堪
閱棩閵峰敭浠ｈ〃锛堣┎鑱蜂綅涓昏璨犺铂绂忓缓娉夊窞鍦板崁锛岃矤璨亷涓夌敳閱櫌閵峰敭鑰呭劒鍏堣€冩叜锛�
涓昏鑱疯铂锛�
1. 绌嶆サ瀵︽柦鎵€杞勯啱闄㈠勾銆佸銆佹湀搴﹂啱钘ラ姺鍞▓鍔冿紝鍚堢悊鍒嗛厤鍜屽鏂介姺鍞不鐢ㄩ爯绠楋紱
2. 閰嶅悎钀藉甯傚牬閮ㄧ殑鎺ㄥ唬娲诲嫊锛屼互鍙婂叾浠栭儴闁€锛堣唱閲忋€佽病鍕欏拰浜哄姏璩囨簮绛夛級宸ヤ綔锛�
3. 閱櫌涓婇噺缍鑸囧鎴堕枊鐧硷紱
4. 鍗斿姪鍟嗗嫏閮ㄥ仛濂介姺鍞▊鍠€佸饱琛岃垏绠＄悊宸ヤ綔锛�
5. 鎸夋檪瀹屾垚宸ヤ綔鍫卞憡锛�
6. 瀛哥繏鐢㈠搧鐭ヨ瓨鍜屾彁楂樺伐浣滄妧鑳斤紱
7. 瀹屾垚涓婄礆浜や粯鐨勫叾浠栦换鍕欍€�
浠昏伔璩囨牸锛�
1. 閱鐩搁棞灏堟キ鎴栫稉婵熴€佺鐞嗙浉闂滃皥妤紝澶у灏堢浠ヤ笂瀛告锛�
2. 2骞村強浠ヤ笂鑷ㄥ簥閱棩閵峰敭宸ヤ綔缍撻锛堟湁楠ㄧ銆侀ⅷ婵曠銆佺毊绉戠瓑鑷ㄥ簥鐢ㄨ棩鎺ㄥ唬鍙婇姺鍞稉椹椾匠锛夛紱
3. 閫氭泬灏堟キ鍙婃キ鍕欑煡璀橈紝鎺屾彙鍏徃鎵€缍撶嚐鐢㈠搧澶栬妤嫊鎱嬶紝鎺屾彙甯傚牬鐕熼姺鐩搁棞鐭ヨ瓨锛屼簡瑙ｅ叕鍙告墍缍撶嚐鐢㈠搧鎶€琛撶煡璀橈紱
4. 鐔熺反浣跨敤WORD,EXCEL锛孭OWERPOINT绛夎睛鍏粺浠讹紝鍏峰倷缍茬怠鐭ヨ瓨锛岃瑳瑾茶兘鍔涳紱
5. 鑹ソ鐨勮嫳瑾炴噳鐢ㄨ兘鍔涳紱
6. 浜洪殯鑳藉姏銆佹簼閫氳兘鍔涖€佸奖闊垮姏銆佽▓鍔冭垏鍩疯鑳藉姏銆佸鎴舵湇鍕欒兘鍔涖€�
浼佹キ绨′粙
涓婃捣涓俊鍦嬪仴閱棩鐧煎睍鏈夐檺鍏徃
涓婃捣涓俊鍦嬪仴閱棩鐧煎睍鏈夐檺鍏徃鐐轰笂娴蜂腑淇″湅鍋ヨ棩妤偂浠芥湁闄愬叕鍙稿叏璩囧瓙鍏徃銆�
涓婃捣涓俊鍦嬪仴钘ユキ鑲′唤鏈夐檺鍏徃锛堜互涓嬬啊绋扁€滀腑淇″湅鍋モ€濓級鏄敱涓湅涓俊闆嗗湗鏈夐檺鍏徃鏃椾笅涓俊娉板瘜鏈夐檺鍏徃鎶曡硣鎺ц偂鐨勭敓鐗╅啱钘ラ珮鏂版妧琛撲紒妤€傚叕鍙歌嚜2002骞村壍寤轰互渚嗭紝灏堟敞浜庢姉楂旇棩鐗╃殑鐮旂櫦銆佷腑瑭﹀拰鐢㈡キ鍖栵紝鐝惧凡鐧煎睍鎴愮偤鍦嬪収鎶楅珨鍒惰棩闋樺煙鐨勯牁杌嶄紒妤紝鎻愪緵瑕嗚搵娌荤檪鑵槫銆佽嚜韬厤鐤€х柧鐥呫€佹姉鍣ㄥ畼绉绘鎺掓枼鍙嶆噳绛夐噸澶х柧鐥呴牁鍩熺殑闈跺悜钘ョ墿銆�
浣滅偤涓€瀹朵互鐮旂櫦鐐哄熀绀庣殑鐢熺墿鍒惰棩鍏徃锛屼腑淇″湅鍋ュ凡鎴愬姛妲嬪缓浜嗘姉楂旇棩鐗╅枊鐧煎拰鐢㈡キ鍖栧钩鑷哄苟鎺屾彙鏍稿績鎶€琛擄紝鍏峰倷鎸佺簩闁嬬櫦鏂拌棩鐨勫壍鏂拌兘鍔涖€傚叕鍙哥敓鐢㈣妯′綅灞呰妤墠鍒椼€�
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China鈥檚 domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ鈥檚 strategic planning. The company鈥檚 product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.
Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ鈥檚 wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.
鐝剧敱浜庡叕鍙哥櫦灞曢渶瑕侊紝瑾犺仒鍏锋湁鍓垫柊绮剧鍜屾垚灏变簨妤悊鎯崇殑鍎浜烘墠鍔犵洘銆�
璜嬬鍚堟浠剁殑鎳夎仒鑰呭皣涓嫳鏂囩啊姝风瓑淇℃伅鐧奸€丒-mail鑷筹細cpgjhr@cpgj-pharm.com 锛堣珛鍦ㄩ兊浠堕鐩笂娉ㄦ槑鎳夎仒鑱蜂綅绛変俊鎭級
[灞曢枊鍏ㄦ枃]
[鏀剁府鍏ㄦ枃]
